BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35098660)

  • 41. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
    Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
    BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors.
    Kulikowska de Nałęcz A; Ciszak L; Usnarska-Zubkiewicz L; Pawlak E; Frydecka I; Szmyrka M; Kosmaczewska A
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982802
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma.
    Schuhmacher B; Rengstl B; Döring C; Bein J; Newrzela S; Brunnberg U; Kvasnicka HM; Vornanen M; Küppers R; Hansmann ML; Hartmann S
    Oncotarget; 2016 Nov; 7(44):72197-72210. PubMed ID: 27708232
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives.
    Lin N; Song Y; Zhu J
    Chin J Cancer Res; 2020 Jun; 32(3):303-318. PubMed ID: 32694896
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The influence of programmed cell death ligand 2 (PD-L2) expression on survival outcome and tumor microenvironment in diffuse large B cell lymphoma.
    Krittikarux S; Wudhikarn K; Tangnuntachai N; Assanasen T; Sukswai N; Asawapanumas T; Chanswangphuwana C
    Leuk Lymphoma; 2020 Dec; 61(14):3395-3403. PubMed ID: 32820659
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationship between the absolute lymphocyte count/absolute monocyte count ratio, soluble interleukin 2 receptor level, serum programmed cell death 1 level, and the prognosis of patients with diffuse large B-cell lymphoma.
    Li C; Li W; Xu G; You M; Wu W; Kuang L
    Ann Palliat Med; 2021 Oct; 10(10):10938-10945. PubMed ID: 34763456
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
    Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
    Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma.
    Tobin JWD; Bednarska K; Campbell A; Keane C
    Cells; 2021 May; 10(5):. PubMed ID: 34068762
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.
    Keane C; Vari F; Hertzberg M; Cao KA; Green MR; Han E; Seymour JF; Hicks RJ; Gill D; Crooks P; Gould C; Jones K; Griffiths LR; Talaulikar D; Jain S; Tobin J; Gandhi MK
    Lancet Haematol; 2015 Oct; 2(10):e445-55. PubMed ID: 26686046
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The immune checkpoint expression in the tumor immune microenvironment of DLBCL: Clinicopathologic features and prognosis.
    Ma J; Pang X; Li J; Zhang W; Cui W
    Front Oncol; 2022; 12():1069378. PubMed ID: 36561512
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
    Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
    Front Immunol; 2022; 13():950213. PubMed ID: 36072582
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma.
    Ballhausen A; Ben Hamza A; Welters C; Dietze K; Bullinger L; Rahn HP; Hartmann S; Hansmann ML; Hansmann L
    Cancer Immunol Immunother; 2023 Feb; 72(2):515-521. PubMed ID: 35947165
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.
    Koh YW; Jeon YK; Yoon DH; Suh C; Huh J
    Tumour Biol; 2016 Jun; 37(6):7507-14. PubMed ID: 26678894
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma].
    Maruyama D
    Rinsho Ketsueki; 2020; 61(8):890-900. PubMed ID: 32908053
    [TBL] [Abstract][Full Text] [Related]  

  • 57. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma without mediastinal disease: mimicking nodular sclerosis classical Hodgkin lymphoma.
    Iwaki N; Sato Y; Kurokawa T; Maeda Y; Ohno K; Takeuchi M; Takata K; Orita Y; Nakao S; Yoshino T
    Med Mol Morphol; 2013 Sep; 46(3):172-6. PubMed ID: 23512149
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma.
    Ozturk V; Yikilmaz AS; Kilicarslan A; Bakanay SM; Akinci S; Dilek İ
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e375-e381. PubMed ID: 32295735
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors.
    Vardhana S; Cicero K; Velez MJ; Moskowitz CH
    Oncologist; 2019 Jan; 24(1):86-95. PubMed ID: 30082490
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients.
    Karihtala K; Leivonen SK; Karjalainen-Lindsberg ML; Chan FC; Steidl C; Pellinen T; Leppä S
    Blood Adv; 2022 Mar; 6(6):1919-1931. PubMed ID: 34941990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.